Literature DB >> 19539874

Antigen loss from antibody-coated red blood cells.

James C Zimring1, Chantel M Cadwell, Steven L Spitalnik.   

Abstract

Clinically significant signs and symptoms of hemolysis can result from the transfusion of crossmatch incompatible blood, the development of anti-red blood cell (RBC) alloantibodies posttransfusion, or the development of autoantibodies to RBCs (ie, autoimmune hemolytic anemia). However, a less understood and poorly appreciated phenomenon is when an antibody induces the loss of its target antigen without significant damage to the cells themselves. This has been referred to as "depressed antigen," "antigen suppression," "weakened antigenicity," and "antigen loss." This phenomenon has been observed for multiple blood group antigens on human RBCs, in addition to antigens on leukocytes, platelets, neurons, and neoplastic cells. This review discusses the published human case reports of antigen loss in each of the contexts described above and describes several experimental models, including whole animal models and in vitro culture systems. Our current understanding of the cellular and molecular mechanisms is discussed, and the role of antigen loss phenomena in both normal immune function and in disease states is reviewed.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19539874     DOI: 10.1016/j.tmrv.2009.03.002

Source DB:  PubMed          Journal:  Transfus Med Rev        ISSN: 0887-7963


  16 in total

1.  Neutralizing anti-gH antibody of Varicella-zoster virus modulates distribution of gH and induces gene regulation, mimicking latency.

Authors:  Kimiyasu Shiraki; Tohru Daikoku; Masaya Takemoto; Yoshihiro Yoshida; Kazuhiro Suzuki; Yasushi Akahori; Toshiomi Okuno; Yoshikazu Kurosawa; Yoshizo Asano
Journal:  J Virol       Date:  2011-06-01       Impact factor: 5.103

Review 2.  Use of mouse models to study the mechanisms and consequences of RBC clearance.

Authors:  E A Hod; S A Arinsburg; R O Francis; J E Hendrickson; J C Zimring; S L Spitalnik
Journal:  Vox Sang       Date:  2010-03-21       Impact factor: 2.144

3.  A novel role for C3 in antibody-induced red blood cell clearance and antigen modulation.

Authors:  Kathryn R Girard-Pierce; Sean R Stowell; Nicole H Smith; C Maridith Arthur; Harold C Sullivan; Jeanne E Hendrickson; James C Zimring
Journal:  Blood       Date:  2013-07-22       Impact factor: 22.113

4.  Anti-KEL sera prevents alloimmunization to transfused KEL RBCs in a murine model.

Authors:  Sean R Stowell; C Maridith Arthur; Kathryn R Girard-Pierce; Harold C Sullivan; Manjula Santhanakrishnan; Prabitha Natarajan; Seema R Patel; Christopher A Tormey; James C Zimring; Jeanne E Hendrickson
Journal:  Haematologica       Date:  2015-07-16       Impact factor: 9.941

5.  Alloantibodies to a paternally derived RBC KEL antigen lead to hemolytic disease of the fetus/newborn in a murine model.

Authors:  Sean R Stowell; Kate L Henry; Nicole H Smith; Krystalyn E Hudson; Greg R Halverson; Jaekeun C Park; Ashley M Bennett; Kathryn R Girard-Pierce; C Maridith Arthur; Silvia T Bunting; James C Zimring; Jeanne E Hendrickson
Journal:  Blood       Date:  2013-06-25       Impact factor: 22.113

6.  Clinically significant anti-KEL RBC alloantibodies are transferred by breast milk in a murine model.

Authors:  M Santhanakrishnan; C A Tormey; P Natarajan; J Liu; J E Hendrickson
Journal:  Vox Sang       Date:  2016-03-07       Impact factor: 2.144

7.  Antigen modulation as a potential mechanism of anti-KEL immunoprophylaxis in mice.

Authors:  Jingchun Liu; Manjula Santhanakrishnan; Prabitha Natarajan; David R Gibb; Stephanie C Eisenbarth; Christopher A Tormey; Alexa J Siddon; Sean R Stowell; Donald R Branch; Jeanne E Hendrickson
Journal:  Blood       Date:  2016-09-29       Impact factor: 22.113

Review 8.  Factors Influencing RBC Alloimmunization: Lessons Learned from Murine Models.

Authors:  Alex B Ryder; James C Zimring; Jeanne E Hendrickson
Journal:  Transfus Med Hemother       Date:  2014-11-17       Impact factor: 3.747

9.  Daratumumab (anti-CD38) induces loss of CD38 on red blood cells.

Authors:  Harold C Sullivan; Christian Gerner-Smidt; Ajay K Nooka; Connie M Arthur; Louisa Thompson; Amanda Mener; Seema R Patel; Marianne Yee; Ross M Fasano; Cassandra D Josephson; Richard M Kaufman; John D Roback; Sagar Lonial; Sean R Stowell
Journal:  Blood       Date:  2017-04-03       Impact factor: 25.476

10.  Anti-RhD reduces levels of detectable RhD antigen following anti-RhD infusion.

Authors:  Harold C Sullivan; Connie M Arthur; Louisa Thompson; Seema R Patel; Sean R Stowell; Jeanne E Hendrickson; Alan H Lazarus
Journal:  Transfusion       Date:  2018-02       Impact factor: 3.337

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.